HPV-16/18 vaccine

BIOLOGICAL3 trials

Conditions

CIN - Cervical Intraepithelial NeoplasiaCervical CancerCervical Intraepithelial NeoplasiaHuman Papilloma Virus Infection Type 16Human Papilloma Virus Infection Type 18Human PapillomavirusHuman Papillomavirus InfectionPersistent Infection

Phase 2

Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females

CompletedNCT02740777

Shanghai Zerun Biotechnology Co.,LtdCervical Intraepithelial Neoplasia, Human Papillomavirus, Persistent Infection

Start: 2016-02-29End: 2019-07-31Updated: 2023-04-13

Phase 3

A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.

CompletedNCT02733068

Shanghai Zerun Biotechnology Co.,LtdCervical Intraepithelial Neoplasia, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18

Start: 2014-11-02End: 2020-01-16Updated: 2022-12-19

Unknown Phase

Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women

Active, not recruitingNCT06776055

Shanghai Zerun Biotechnology Co.,LtdCervical Cancer, CIN - Cervical Intraepithelial Neoplasia, Human Papillomavirus Infection +2

Start: 2023-03-27End: 2026-06-30Updated: 2025-01-15

Related Papers

Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.